Trials / Not Yet Recruiting
Not Yet RecruitingNCT07076290
A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Rise Therapeutics LLC · Industry
- Sex
- All
- Age
- 40 Years – 82 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate chronic obstructive pulmonary disease (COPD)
Detailed description
Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and scored measure of their chronic obstructive pulmonary disease (COPD). Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | R-3750 | R-3750 DP; Lactococcus lactis expressing Surface Layer Protein A (SlpA) |
Timeline
- Start date
- 2026-09-01
- Primary completion
- 2028-04-30
- Completion
- 2028-12-31
- First posted
- 2025-07-22
- Last updated
- 2026-01-29
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07076290. Inclusion in this directory is not an endorsement.